Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Spyre Therapeutics Inc (SYRE)

Spyre Therapeutics Inc (SYRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,736,934
  • Shares Outstanding, K 78,540
  • Annual Sales, $ 0 K
  • Annual Income, $ -155,200 K
  • EBIT $ -210 M
  • EBITDA $ -221 M
  • 60-Month Beta 2.93
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.78

Options Overview Details

View History
  • Implied Volatility 126.20% (+0.52%)
  • Historical Volatility 69.73%
  • IV Percentile 64%
  • IV Rank 40.72%
  • IV High 222.63% on 09/16/25
  • IV Low 59.96% on 08/18/25
  • Expected Move (DTE 12) 13.36 (28.08%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 13
  • Volume Avg (30-Day) 176
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 3,747
  • Open Int (30-Day) 1,948
  • Expected Range 34.22 to 60.94

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.67
  • Number of Estimates 5
  • High Estimate $-0.59
  • Low Estimate $-0.76
  • Prior Year $-0.74
  • Growth Rate Est. (year over year) +9.46%

Price Performance

See More
Period Period Low Period High Performance
1-Month
38.36 +24.04%
on 03/06/26
51.06 -6.82%
on 03/31/26
+5.09 (+11.98%)
since 03/02/26
3-Month
28.00 +69.93%
on 01/05/26
51.06 -6.82%
on 03/31/26
+17.00 (+55.59%)
since 01/02/26
52-Week
10.91 +336.11%
on 04/09/25
51.06 -6.82%
on 03/31/26
+32.09 (+207.17%)
since 04/02/25

Most Recent Stories

More News
Spyre Therapeutics Announces Grants of Inducement Awards

WALTHAM, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies...

SYRE : 47.58 (-2.70%)
Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026

Recruitment for the rheumatoid arthritis (RA) sub-study of the SKYWAY basket trial is complete; Week 12 topline data now expected in Q3 2026 Recruitment for the psoriatic arthritis (PsA) and axial...

SYRE : 47.58 (-2.70%)
Spyre Therapeutics Announces Grants of Inducement Awards

WALTHAM, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies...

SYRE : 47.58 (-2.70%)
Spyre Therapeutics to Participate in Upcoming March Investor Conferences

WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine...

SYRE : 47.58 (-2.70%)
Spyre Therapeutics: Q4 Earnings Snapshot

Spyre Therapeutics: Q4 Earnings Snapshot

SYRE : 47.58 (-2.70%)
Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

On track for 6 proof-of-concept readouts in 2026 across the SKYLINE and SKYWAY Phase 2 trials  Part A readouts from SKYLINE platform trial in ulcerative colitis ("UC") expected to begin in the second...

SYRE : 47.58 (-2.70%)
Spyre Therapeutics Announces Presentations at the 21st ECCO Congress Supporting Differentiated Profile of SPY003 and Novel Animal Studies Demonstrating Superiority of Combination Approach

WALTHAM, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine...

SYRE : 47.58 (-2.70%)
Spyre Therapeutics Announces Grants of Inducement Awards

WALTHAM, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies...

SYRE : 47.58 (-2.70%)
Spyre Therapeutics Announces Grants of Inducement Awards

WALTHAM, Mass., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies...

SYRE : 47.58 (-2.70%)
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2

“6 in ’26” expected proof-of-concept (POC) readouts across SKYLINE and SKYWAY trials SKYLINE platform trial in ulcerative colitis (UC) recruiting faster than expected with SPY001 enrollment...

SYRE : 47.58 (-2.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Spyre Therapeutics is a biotechnology company which aims to create inflammatory bowel disease products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches for patient selection. Spyre Therapeutics, formerly known as Aeglea BioTherapeutics Inc., is based...

See More

Key Turning Points

3rd Resistance Point 50.70
2nd Resistance Point 49.55
1st Resistance Point 48.57
Last Price 47.58
1st Support Level 46.43
2nd Support Level 45.28
3rd Support Level 44.29

See More

52-Week High 51.06
Last Price 47.58
Fibonacci 61.8% 35.72
Fibonacci 50% 30.99
Fibonacci 38.2% 26.25
52-Week Low 10.91

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.